Our findings indicate that ECH exerts its anti-HCC effect by activating the TP53/SLC7A11/GPX4 pathway, specifically through increasing TP53 while inhibiting SLC7A11 and GPX4 expression. Here, TP53 is linked to hepatocellular carcinoma.